Cingulate Inc. (CING)Healthcare | Biotechnology | Kansas City, United States | NasdaqCM
5.33 USD
-0.12
(-2.114%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 5.31 -0.01 (-0.015%) ⇩ (Aug. 28, 2026, 7:57 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:44 a.m. EDT
The investment case for Cingulate is currently broken by a catastrophic multi-year price collapse. Despite the company's 'strong buy' analyst consensus and a director buying shares, the market has punished the stock relentlessly, erasing nearly 99% of its value over the last three years. The price trajectory shows three consecutive years of negative returns, a clear signal that the market views the business fundamentals as deteriorating rather than improving. While the pipeline has patent wins, the failure of the ADHD treatment due to manufacturing issues and the resulting stock implosion suggest the commercial reality is far worse than the optimistic headlines imply. The options market confirms this fear, with traders aggressively buying cheap insurance against further drops while ignoring the potential for a recovery. Until the company demonstrates a sustained turnaround in revenue and margins, this remains a high-risk speculative vehicle where the odds favor further downside. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.206892 |
| MSTL | 0.225654 |
| AutoARIMA | 0.355350 |
| AutoTheta | 0.391942 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 0.80 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.002 |
| Excess Kurtosis | 1.60 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 26.807 |
| Market Cap | 77,435,224 |
| Forward P/E | -6.05 |
| Beta | -0.91 |
| Website | https://www.cingulate.com |
As of Aug. 22, 2026, 3:44 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in deep out-of-the-money puts (strikes at 2.5) expiring in late August and November. This 'naked put' positioning suggests a high probability of a sharp decline or a failed catalyst event. Conversely, call volume is concentrated in the money, indicating a speculative attempt to catch a bounce, but the overwhelming put weight creates a significant tail-risk skew.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.45844507 |
| Address1 | 1,901 West 47th Place |
| All Time High | 1,236.0 |
| All Time Low | 1.8 |
| Ask | 6.91 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 168,830 |
| Average Daily Volume3 Month | 367,361 |
| Average Volume | 367,361 |
| Average Volume10Days | 168,830 |
| Beta | -0.906 |
| Bid | 3.89 |
| Bid Size | 2 |
| Book Value | 1.689 |
| City | Kansas City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.325 |
| Current Ratio | 3.5 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 5.48 |
| Day Low | 5.2559 |
| Debt To Equity | 26.807 |
| Display Name | Cingulate |
| Ebitda | -24,472,254 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.261 |
| Enterprise Value | 55,323,284 |
| Eps Current Year | -2.1875 |
| Eps Forward | -0.88 |
| Eps Trailing Twelve Months | -3.49 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.0208 |
| Fifty Day Average Change | 0.3041997 |
| Fifty Day Average Change Percent | 0.06058789 |
| Fifty Two Week Change Percent | 45.844505 |
| Fifty Two Week High | 11.89 |
| Fifty Two Week High Change | -6.5650005 |
| Fifty Two Week High Change Percent | -0.5521447 |
| Fifty Two Week Low | 3.16 |
| Fifty Two Week Low Change | 2.1649997 |
| Fifty Two Week Low Change Percent | 0.6851265 |
| Fifty Two Week Range | 3.16 - 11.89 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,638,973,800,000 |
| Float Shares | 14,205,328 |
| Forward Eps | -0.88 |
| Forward P E | -6.051136 |
| Free Cashflow | -12,838,706 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 14 |
| Fullday Change | -0.115 |
| Fullday Change Percent | -2.11398 |
| Fullday Price | 5.31 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -8,521,635 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.28285998 |
| Held Percent Institutions | 0.1262 |
| Implied Shares Outstanding | 14,541,826 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-12-08 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,723,161,600 |
| Last Split Factor | 1:12 |
| Long Business Summary | Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas. |
| Long Name | Cingulate Inc. |
| Market | us_market |
| Market Cap | 77,435,224 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1674914781 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -28,809,044 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 78,962,115 |
| Number Of Analyst Opinions | 5 |
| Open | 5.48 |
| Operating Cashflow | -20,654,108 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 913 942 2300 |
| Post Market Change | -0.0149998665 |
| Post Market Change Percent | -0.28168765 |
| Post Market Price | 5.31 |
| Post Market Time | 1,787,961,477 |
| Previous Close | 5.44 |
| Price Eps Current Year | -2.4342856 |
| Price Hint | 2 |
| Price To Book | 3.1527529 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.3 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -0.115 |
| Regular Market Change Percent | -2.11398 |
| Regular Market Day High | 5.48 |
| Regular Market Day Low | 5.2559 |
| Regular Market Day Range | 5.2559 - 5.48 |
| Regular Market Open | 5.48 |
| Regular Market Previous Close | 5.44 |
| Regular Market Price | 5.325 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 108,405 |
| Return On Assets | -0.66940004 |
| Return On Equity | -1.9874 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 14,541,826 |
| Shares Percent Shares Out | 0.08270001 |
| Shares Short | 1,203,157 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,678,218 |
| Short Name | Cingulate Inc. |
| Short Percent Of Float | 0.1154 |
| Short Ratio | 7.45 |
| Source Interval | 15 |
| State | KS |
| Symbol | CING |
| Target High Price | 44.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 21.2 |
| Target Median Price | 20.0 |
| Total Cash | 28,402,820 |
| Total Cash Per Share | 1.953 |
| Total Debt | 6,290,880 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.49 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.231375 |
| Two Hundred Day Average Change | 0.09362459 |
| Two Hundred Day Average Change Percent | 0.017896745 |
| Type Disp | Equity |
| Volume | 108,405 |
| Website | https://www.cingulate.com |
| Zip | 66,205 |